A New PARP-oriented Strategy for Treating Cellular Injury
This article was originally published in Start Up
Executive Summary
PARP inhibition's been hot, especially as it relates to cancer therapy: witness the Genentech-Inotek deal in September 2006. Now researchers at Johns Hopkins have described a new mechanism triggered by PARP activation that causes cell death following reperfusion injury--information that could provider drug developers with a new set of targets for treating a host of conditions.
You may also be interested in...
Genentech and Inotek Pair Up in PARP Inhibition
For the first time, oncology drug development is being grounded in the ability to take advantage of a readily identifiable genetic flaw in certain types of tumor cells. Research reveals that tumor cells containing the BRCA1 or BRCA2 gene variants are exquisitely sensitive to attack by inhibitors of poly (ADP-ribose) polymerase, or PARP. Now comes a deal between PARP specialist Inotek Pharmaceuticals and Genentech.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.